Acadia Pharmaceuticals Inc
A biopharmaceutical company that develops and sells medicines for brain and nervous-system conditions. Its drug NUPLAZID was the first FDA-approved treatment for the hallucinations and delusions that can accompany Parkinson's disease, and its DAYBUE is the first and only approved therapy for Rett syndrome, a rare genetic disorder. Acadia began in 1993 as a small Vermont lab called Receptor Technologies, then took its name from Acadia National Park when it moved to San Diego. It originally set out to treat Parkinson's symptoms, but an early twist of fate redirected the science toward tackling hallucinations instead.
Granted 1.47M · Bought 18.84M
Granted 260.8K · Bought 3.51M
Bought 4.33M
Sold 80.0K
Granted 1.08M · Sold 901.2K
Granted 181.0K · Sold 31.5K
Granted 536.8K · Sold 552.5K
Granted 530.0K · Sold 535.4K
Granted 188.7K · Sold 130.0K
Granted 115.4K · Sold 57.1K
Granted 448.1K · Sold 386.8K
Granted 96.2K · Sold 54.1K
Granted 34.0K · Bought 10.0K
Granted 42.1K · Bought 1.0K
Granted 225.3K · Bought 3.0K · Sold 183.7K
Granted 42.9K · Sold 6.5K
Granted 32.9K
Granted 240.5K · Sold 319.0K
Granted 244.2K · Sold 221.0K
Granted 20.0K
Granted 61.0K · Sold 119.5K
Granted 145.5K · Sold 128.5K
Granted 23.5K · Sold 11.6K
Granted 62.8K · Sold 57.7K
Granted 25.0K · Sold 27.5K
Granted 98.4K · Sold 86.3K
Granted 20.5K · Sold 10.8K
Granted 61.7K · Sold 51.1K
Granted 43.0K · Sold 43.0K
Granted 163.4K · Sold 165.4K
Granted 159.2K · Sold 152.0K
Granted 180.8K · Sold 172.3K
Granted 6.7K · Sold 3.4K
Granted 2.0K
Granted 28.9K · Sold 33.3K
Granted 60.0K · Sold 60.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +6 co-filersDirector, 10% owner · 41 transactions | — | 68.07Mas of Nov 2018 | 1.47M | 18.84M | — |
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 63 transactions | — | 39.49M | 260.8K | 3.51M | — |
| Baker Bros Advisors LLC +5 co-filersDirector, 10% owner · 30 transactions | — | 830.7Kas of Jun 2013 | — | 4.33M | — |
| Brann Mark RPresident & CSO, Director · 10 transactions | — | 370.3Kas of Jun 2006 | — | — | 80.0K |
| Davis StephenCEO, Director · 68 transactions | — | 186.6Kas of Aug 2024 | 1.08M | — | 901.2K |
| Gray Mary AnnDirector · 16 transactions | — | 149.5Kas of Jun 2016 | 181.0K | — | 31.5K |
| Hacksell UliCEO, Director · 122 transactions | — | 115.5Kas of Feb 2015 | 536.8K | — | 552.5K |
| Baity GlennEVP AND GC · 70 transactions | — | 83.7Kas of Jan 2018 | 530.0K | — | 535.4K |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · 57 transactions | — | 66.1K | 188.7K | — | 130.0K |
| Teehan BrendanEVP, COO, HEAD OF COMMERCIAL · 36 transactions | — | 62.1Kas of Nov 2024 | 115.4K | — | 57.1K |
| Stankovic Srdjan R.President · 52 transactions | — | 61.2Kas of Nov 2022 | 448.1K | — | 386.8K |
| Kim Austin D.EVP,General Counsel, Secretary · 30 transactions | — | 46.9Kas of Jan 2024 | 96.2K | — | 54.1K |
| Soland Daniel BDirector · 9 transactions | — | 44.0Kas of May 2025 | 34.0K | 10.0K | — |
| Harrigan EdmundDirector · 7 transactions | — | 43.1K | 42.1K | 1.0K | — |
| Iversen Leslie LDirector · 25 transactions | — | 36.1Kas of Apr 2016 | 225.3K | 3.0K | 183.7K |
| Garofalo Elizabeth A.Director · 10 transactions | — | 33.5K | 42.9K | — | 6.5K |
| Ndu AdoraDirector · 5 transactions | — | 32.9K | 32.9K | — | — |
| Aasen Thomas HEXEC VP, CFO AND CBO · 73 transactions | — | 23.8Kas of Apr 2014 | 240.5K | — | 319.0K |
| Brege LauraDirector · 31 transactions | — | 23.2K | 244.2K | — | 221.0K |
| Tolf Bo-RagnarVP/Mg. Dir. ACADIA Pharma AB · 2 transactions | — | 20.0Kas of Jul 2009 | 20.0K | — | — |
| Mills RogerEVP, DEVELOPMENT AND CMO · 5 transactions | — | 18.6Kas of Nov 2014 | 61.0K | — | 119.5K |
| Kaplan Lester J PH DDirector · 16 transactions | — | 17.0Kas of Aug 2015 | 145.5K | — | 128.5K |
| Owen Adams CatherineChief Executive Officer, Director · 2 transactions | — | 14.8K | 23.5K | — | 11.6K |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER · 54 transactions | — | 13.1K | 62.8K | — | 57.7K |
| Lundstrom BrianSr. VP, Bus. Devt. · 20 transactions | — | 12.5Kas of Dec 2007 | 25.0K | — | 27.5K |
| Daly James MDirector · 13 transactions | — | 12.1K | 98.4K | — | 86.3K |
| Rhodes Jennifer JEVP, CHIEF LEGAL OFFICER, SEC · 4 transactions | — | 11.3K | 20.5K | — | 10.8K |
| Ridloff ElenaEVP and CFO · 14 transactions | — | 10.6Kas of Apr 2021 | 61.7K | — | 51.1K |
| Borer Michael TDirector · 7 transactions | — | 10.0Kas of Jan 2015 | 43.0K | — | 43.0K |
| Moore Terrence OEVP, CHIEF COMMERCIAL OFFICER · 10 transactions | — | 9.5Kas of Feb 2017 | 163.4K | — | 165.4K |
| Yang Michael J.EVP and CCO · 21 transactions | — | 9.2Kas of Jan 2021 | 159.2K | — | 152.0K |
| Rasmussen TorstenDirector · 28 transactions | — | 8.5Kas of Feb 2015 | 180.8K | — | 172.3K |
| Thompson Elizabeth H.Z.EVP, Head of Research & Dev · 2 transactions | — | 3.3K | 6.7K | — | 3.4K |
| Poole JonathanDirector · 1 transaction | — | 2.0K | 2.0K | — | — |
| Miller Eric AlejandroController & PAO · 10 transactions | — | 417as of Oct 2019 | 28.9K | — | 33.3K |
| Wells William McDowallDirector · 9 transactions | — | 0as of Nov 2014 | 60.0K | — | 60.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +22.12M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.